Novogen Limited is engaged in pharmaceutical research and development, and marketing of consumer healthcare products. The Company has three segments: Drug Development, Oncology Drug Program, Consumer Business and Wound Healing. Drug Development includes the discovery of new compounds and the early stage screening for bioactivity of such compounds through both in vivo and in vitro testing. Oncology Drug Program involves the development of selected oncology drug candidates, which have indicated bioactivity against cancer cells through clinical trial programs to assess safety and efficacy. Wound Healing is a separate technology based on Beta-1 Glucan to aid in the management of wounds. The Company�s clinical development program run through Novogen�s subsidiaries Marshall Edwards, Inc. (MEI) and Glycotex, Inc. (Glycotex). In October 2013, Novogen Limited acquired a drug technology.